EFFICIENCY OF CHEMOTHERAPY WITH BEDAQUILINE IN DRUG RESISTANT PULMONARY TUBERCULOSIS PATIENTS
https://doi.org/10.21292/2075-1230-2018-96-2-22-26
Abstract
The objective: to evaluate the efficiency of chemotherapy with bedaquiline in pulmonary tuberculosis patients with multiple drug resistance Subjects and methods. The chemotherapy efficiency was studied in 70 tuberculosis patients with extensive (XDR) or multiple (MDR) drug resistance who were treated in clinics of Central Tuberculosis Research Institute All patients were divided into 3 groups: Group 1 (10 persons) included MDR TB patients, Group 2 (32 persons) included pre-XDR TB patients, Group 3 (28 persons) included XDR TB patients
Results of the study. High treatment efficiency in this difficult category of pulmonary tuberculosis patients with MDR and XDR was achieved when bedaquiline was added to the chemotherapy regimen Upon the completion of the main treatment course with bedaquiline, in the group of patients with MDR and pre-XDR the sputum conversion was achieved in 100%, and in XDR tuberculosis patients the sputum conversion rate made 893% The long-term treatment course with bedaquiline promoted the fastest sputum conversion, healing of cavities in the lungs of patients with disseminated tuberculosis and XDR, and it was not associated with a higher frequency of adverse events
About the Authors
A. M. Tikhonov
Central Research Institute of Tuberculosis, Moscow
Russian Federation
Phthisiologist of the 1st Therapy Department
Russian Federation
Phthisiologist of the 1st Therapy Department
M. V. Burаkovа
Central Research Institute of Tuberculosis, Moscow;
People's Friendship University of Russia, Moscow
Russian Federation
Phthisiologist of the 1st Therapy Department
Russian Federation
Phthisiologist of the 1st Therapy Department
E. V. Vаniev
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow
Russian Federation
Candidate of Medical Sciences, Head of Consulting and Diagnostic Department
Russian Federation
Candidate of Medical Sciences, Head of Consulting and Diagnostic Department
V. V. Romаnov
Central Research Institute of Tuberculosis, Moscow
Russian Federation
Doctor of Medical Sciences, Professor, Head of Tuberculosis Control Department
Russian Federation
Doctor of Medical Sciences, Professor, Head of Tuberculosis Control Department
I. A. Vаsilyevа
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow
Russian Federation
Doctor of Medical Sciences, Professor, Director
Russian Federation
Doctor of Medical Sciences, Professor, Director
References
1. Zhukova E.M., Kolpakova T.А., Myshkova E.P., Reykhrud T.А. Experience of using bedaquiline in the integral treatment of the pulmonary tuberculosis patient with extensive drug resistance of M. tuberculosis. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 10, pp. 62-67. (In Russ.)
2. Codecasa L.R., Toumi M., D'Ausilio A., Aiello A., Damele F., Termini R., Uglietti A., Hettle R., Graziano G., De Lorenzo S.J. Mark Access
3. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. Health Policy, 2017, vol. 48, pp. 48-51.
4. Guglielmetti L., Hewison C., Avaliani Z., Hughes J., Kiria N., Lomtadze N., Ndjeka N., Setkina S., Shabangu A., Sikhondze W., Skrahina A., Veziris N., Furin J. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int. J. Tuberc. Lung Dis., 2017, vol. 21, pp. 167-174.
5. Tiberi S., Buchanan R., Caminero J.A., Centis R., Arbex M.A., Salazar M., Potter J., Migliori G.B. The challenge of the new tuberculosis drugs. Presse Med., 2017, vol. 2, pp. 41-51.
6. Wirth D., Dass R., Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Europ. Respir. J., 2016, vol. 48, pp. 182.
Review
For citations:
Tikhonov A.M., Burаkovа M.V., Vаniev E.V., Romаnov V.V., Vаsilyevа I.A. EFFICIENCY OF CHEMOTHERAPY WITH BEDAQUILINE IN DRUG RESISTANT PULMONARY TUBERCULOSIS PATIENTS. Tuberculosis and Lung Diseases. 2018;96(2):22-26. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-2-22-26
Views:
2729
Email this article 